Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutationAlberto Álvarez‐Larrán, C. Besses, J Schwarz et al.|Haematologica|2016Cited by 149
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working GroupHolly L. Geyer, Peihong Zhang, Heidi Kosiorek et al.|Haematologica|2016Cited by 73
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST StudyPaola Guglielmelli, Tiziano Barbui, Arianna Ghirardi et al.|Blood Advances|2021Cited by 66
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needsAllison H. Scotch, Robert Peter Gale, Heidi Kosiorek et al.|Leukemia Research|2017Cited by 27
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study GroupHolly L. Geyer, Ruben A. Mesa, Björn Andréasson et al.|Cancer|2016Cited by 23